<p>在過去的 7 天裏，美國市場保持平穩，但在過去一年中卻顯著上漲了 28%，預計未來幾年收益將以每年 16% 的速度增長。在這樣的環境下，識別那些交易價格低於其內在價值的股票，可以為尋求利用低估機會的投資者提供潛在的機會。</p>
<h3>基於現金流的美國十大低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>Unity Software (U)</td>
<td>$27.72</td>
<td>$55.28</td>
<td>49.9%</td>
</tr>
<tr>
<td>Travere Therapeutics (TVTX)</td>
<td>$44.91</td>
<td>$88.58</td>
<td>49.3%</td>
</tr>
<tr>
<td>Sea (SE)</td>
<td>$85.41</td>
<td>$169.85</td>
<td>49.7%</td>
</tr>
<tr>
<td>Genuine Parts (GPC)</td>
<td>$103.52</td>
<td>$199.62</td>
<td>48.1%</td>
</tr>
<tr>
<td>First Merchants (FRME)</td>
<td>$40.02</td>
<td>$77.51</td>
<td>48.4%</td>
</tr>
<tr>
<td>Fifth Third Bancorp (FITB)</td>
<td>$49.40</td>
<td>$94.92</td>
<td>48%</td>
</tr>
<tr>
<td>FB Financial (FBK)</td>
<td>$53.53</td>
<td>$103.19</td>
<td>48.1%</td>
</tr>
<tr>
<td>Chemung Financial (CHMG)</td>
<td>$65.75</td>
<td>$127.22</td>
<td>48.3%</td>
</tr>
<tr>
<td>AST SpaceMobile (ASTS)</td>
<td>$68.43</td>
<td>$132.99</td>
<td>48.5%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$208.16</td>
<td>$400.51</td>
<td>48%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 151 只低估美國股票的完整列表。</p>
<p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
<h2>Travere Therapeutics (TVTX)</h2>
<p><strong>概述：</strong> Travere Therapeutics, Inc.是一家生物製藥公司，專注於識別、開發和提供針對美國罕見腎臟和代謝疾病的治療，市值為 40.8 億美元。</p>
<p><strong>運營：</strong> 該公司通過開發和商業化針對美國罕見腎臟和代謝疾病的創新療法，產生了 4.9073 億美元的收入。</p>
<p><strong>公允價值折扣估計：</strong> 49.3%</p>
<p>Travere Therapeutics 的交易價格為 44.91 美元，顯著低於其估計的未來現金流價值 88.58 美元，表明其可能在現金流基礎上被低估。該公司報告 2026 年第一季度收入為 1.272 億美元，較去年同期的 8173 萬美元有所增長，淨虧損減少至 3710 萬美元，去年為 4123 萬美元。隨着 FDA 批准 FILSPARI 擴大其市場潛力，Travere 的收入預計將以每年 20.3% 的速度增長，超過美國市場的整體增長預期。</p>
<ul>
<li>根據我們最近的增長報告，Travere Therapeutics 的財務表現似乎有可能超過當前水平。</li>
<li>通過閲讀我們的健康報告，深入瞭解 Travere Therapeutics 的資產負債表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 5 月的 TVTX 折現現金流</p>
<h2>CVR Energy (CVI)</h2>
<p><strong>概述：</strong> CVR Energy, Inc.在美國運營，專注於可再生燃料和石油精煉及營銷，以及氮肥製造，市值為 33.5 億美元。</p>
<p><strong>運營：</strong> 該公司通過在可再生燃料、石油精煉和營銷以及氮肥製造方面的業務產生收入。</p>
<p><strong>公允價值折扣估計：</strong> 28.3%</p>
<p>CVR Energy 的交易價格為 34.2 美元，低於其估計的未來現金流價值 47.72 美元，突顯出基於現金流的潛在低估。儘管最近 2026 年第一季度淨虧損為 1.92 億美元，且面臨盈利挑戰，但該公司預計將在三年內實現盈利，並且預計股本回報率將很高。然而，收入增長仍然緩慢，年增長率為 0.6%，落後於美國市場 11.2% 的預期。</p>
<ul>
<li>根據我們的收益增長報告，CVR Energy 可能準備擴張的跡象。</li>
<li>通過我們的全面財務健康報告，深入瞭解 CVR Energy 的複雜情況。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85096f12-bc2f-4422-bac7-9d19553b4370/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85096f12-bc2f-4422-bac7-9d19553b4370/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 5 月的 CVI 折現現金流</p>
<h2>Unity Software (U)</h2>
<p><strong>概述：</strong> Unity Software Inc.提供一個平台，用於在全球各種設備上開發、部署和增強遊戲及互動體驗，市值約為 118.4 億美元。</p>
<p><strong>運營：</strong> 該公司的軟件解決方案收入為 18.5 億美元。</p>
<p><strong>公允價值折扣估計：</strong> 49.9%</p>
<p>Unity Software 的交易價格為 27.72 美元，顯著低於其估計的未來現金流價值 55.28 美元。儘管最近內部人士出售股票且股價波動，但 Unity 的戰略舉措——如停止 ironSource 廣告網絡和剝離 Supersonic——旨在提升收入增長和利潤率。與 Meta 的長期合作進一步增強了其虛擬現實平台的存在。Unity 預計將在三年內實現盈利，收益預計將以每年 62.95% 的速度大幅增長。</p>
<ul>
<li>我們編制的增長報告表明，Unity Software 的未來前景可能向好。</li>
<li>在這份財務健康報告中解鎖我們對 Unity Software 股票分析的全面見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/81b649ee-0ebc-4d90-9c59-c6ef29110c9d/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/81b649ee-0ebc-4d90-9c59-c6ef29110c9d/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>截至 2026 年 5 月的 U 折現現金流</p>
<h2>下一步</h2>
<ul>
<li>點擊這裏揭示我們基於現金流的 151 只低估美國股票中的隱藏寶藏。</li>
<li>是這些公司的股東之一？確保您不會錯過重要的股票動態，通過在 Simply Wall St 中添加您的投資組合來及時獲取提醒。</li>
<li>通過使用 Simply Wall St 加入聰明投資者的社區。它是免費的，並提供全球市場的專家級分析。</li>
</ul>
<h2>想探索一些替代方案嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠的收入來源來分散您的投資組合，以應對潛在的市場波動。</li>
<li>投資於顯示強勁增長潛力的公司，獲得分析師和管理層的樂觀展望支持。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
<h3>估值是複雜的，但我們在這裏為您簡化它。</h3>
<p>通過我們的詳細分析，發現 Travere Therapeutics 是否可能被低估或高估，分析內容包括 <strong>公允價值估算、潛在風險、股息、內部交易和財務狀況。</strong></p>
<p>獲取免費分析</p>

TVTX

CVR能源

<p>三隻股票被認為交易價格顯著低於其內在價值，呈現出潛在的投資機會。Unity Software (U) 的交易價格為 27.72 美元，比其估計的公允價值 55.28 美元低 49.9%。Travere Therapeutics (TVTX) 的價格為 44.91 美元，比其公允價值 88.58 美元低 49.3%。CVR Energy (CVI) 的交易價格為 34.20 美元，比其估計價值 47.72 美元低 28.3%。儘管當前市場面臨挑戰，這些公司顯示出良好的增長潛力，預計 Unity 的收益增長率為 62.95%，Travere 的收益增長率為 20.3%</p>

<p>Over the last 7 days, the United States market has remained flat, yet it has seen a significant rise of 28% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.</p>
<div class="lb-trans"><p>在過去的 7 天裏，美國市場保持平穩，但在過去一年中卻顯著上漲了 28%，預計未來幾年收益將以每年 16% 的速度增長。在這樣的環境下，識別那些交易價格低於其內在價值的股票，可以為尋求利用低估機會的投資者提供潛在的機會。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In The United States</h3>
<div class="lb-trans"><h3>基於現金流的美國十大低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Unity Software (U)</td>
<td>$27.72</td>
<td>$55.28</td>
<td>49.9%</td>
</tr>
<tr>
<td>Travere Therapeutics (TVTX)</td>
<td>$44.91</td>
<td>$88.58</td>
<td>49.3%</td>
</tr>
<tr>
<td>Sea (SE)</td>
<td>$85.41</td>
<td>$169.85</td>
<td>49.7%</td>
</tr>
<tr>
<td>Genuine Parts (GPC)</td>
<td>$103.52</td>
<td>$199.62</td>
<td>48.1%</td>
</tr>
<tr>
<td>First Merchants (FRME)</td>
<td>$40.02</td>
<td>$77.51</td>
<td>48.4%</td>
</tr>
<tr>
<td>Fifth Third Bancorp (FITB)</td>
<td>$49.40</td>
<td>$94.92</td>
<td>48%</td>
</tr>
<tr>
<td>FB Financial (FBK)</td>
<td>$53.53</td>
<td>$103.19</td>
<td>48.1%</td>
</tr>
<tr>
<td>Chemung Financial (CHMG)</td>
<td>$65.75</td>
<td>$127.22</td>
<td>48.3%</td>
</tr>
<tr>
<td>AST SpaceMobile (ASTS)</td>
<td>$68.43</td>
<td>$132.99</td>
<td>48.5%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$208.16</td>
<td>$400.51</td>
<td>48%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>Unity Software (U)</td>
<td>$27.72</td>
<td>$55.28</td>
<td>49.9%</td>
</tr>
<tr>
<td>Travere Therapeutics (TVTX)</td>
<td>$44.91</td>
<td>$88.58</td>
<td>49.3%</td>
</tr>
<tr>
<td>Sea (SE)</td>
<td>$85.41</td>
<td>$169.85</td>
<td>49.7%</td>
</tr>
<tr>
<td>Genuine Parts (GPC)</td>
<td>$103.52</td>
<td>$199.62</td>
<td>48.1%</td>
</tr>
<tr>
<td>First Merchants (FRME)</td>
<td>$40.02</td>
<td>$77.51</td>
<td>48.4%</td>
</tr>
<tr>
<td>Fifth Third Bancorp (FITB)</td>
<td>$49.40</td>
<td>$94.92</td>
<td>48%</td>
</tr>
<tr>
<td>FB Financial (FBK)</td>
<td>$53.53</td>
<td>$103.19</td>
<td>48.1%</td>
</tr>
<tr>
<td>Chemung Financial (CHMG)</td>
<td>$65.75</td>
<td>$127.22</td>
<td>48.3%</td>
</tr>
<tr>
<td>AST SpaceMobile (ASTS)</td>
<td>$68.43</td>
<td>$132.99</td>
<td>48.5%</td>
</tr>
<tr>
<td>AbbVie (ABBV)</td>
<td>$208.16</td>
<td>$400.51</td>
<td>48%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 151 stocks from our Undervalued US Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 151 只低估美國股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
</div><h2>Travere Therapeutics (TVTX)</h2>
<div class="lb-trans"><h2>Travere Therapeutics (TVTX)</h2>
</div><p><strong>Overview:</strong> Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States, with a market cap of $4.08 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Travere Therapeutics, Inc.是一家生物製藥公司，專注於識別、開發和提供針對美國罕見腎臟和代謝疾病的治療，市值為 40.8 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $490.73 million from the development and commercialization of innovative therapies for rare kidney and metabolic diseases in the United States.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過開發和商業化針對美國罕見腎臟和代謝疾病的創新療法，產生了 4.9073 億美元的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 49.3%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 49.3%</p>
</div><p>Travere Therapeutics is trading at US$44.91, significantly below its estimated future cash flow value of US$88.58, suggesting it may be undervalued based on cash flows. The company reported Q1 2026 revenue of US$127.2 million, up from US$81.73 million a year ago, and reduced its net loss to US$37.1 million from US$41.23 million last year. With FDA approval for FILSPARI expanding its market potential, Travere's revenue is forecasted to grow at 20.3% annually, outpacing the broader U.S market growth expectations.</p>
<div class="lb-trans"><p>Travere Therapeutics 的交易價格為 44.91 美元，顯著低於其估計的未來現金流價值 88.58 美元，表明其可能在現金流基礎上被低估。該公司報告 2026 年第一季度收入為 1.272 億美元，較去年同期的 8173 萬美元有所增長，淨虧損減少至 3710 萬美元，去年為 4123 萬美元。隨着 FDA 批准 FILSPARI 擴大其市場潛力，Travere 的收入預計將以每年 20.3% 的速度增長，超過美國市場的整體增長預期。</p>
</div><ul>
<li>In light of our recent growth report, it seems possible that Travere Therapeutics' financial performance will exceed current levels.</li>
<li>Get an in-depth perspective on Travere Therapeutics' balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>根據我們最近的增長報告，Travere Therapeutics 的財務表現似乎有可能超過當前水平。</li>
<li>通過閲讀我們的健康報告，深入瞭解 Travere Therapeutics 的資產負債表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf?theme=light"/></p>
<p>TVTX Discounted Cash Flow as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 TVTX 折現現金流</p>
</div><h2>CVR Energy (CVI)</h2>
<div class="lb-trans"><h2>CVR Energy (CVI)</h2>
</div><p><strong>Overview:</strong> CVR Energy, Inc. operates in the United States focusing on renewable fuels and petroleum refining and marketing, as well as nitrogen fertilizer manufacturing, with a market cap of $3.35 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CVR Energy, Inc.在美國運營，專注於可再生燃料和石油精煉及營銷，以及氮肥製造，市值為 33.5 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue through its operations in renewable fuels, petroleum refining and marketing, and nitrogen fertilizer manufacturing in the United States.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過在可再生燃料、石油精煉和營銷以及氮肥製造方面的業務產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 28.3%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 28.3%</p>
</div><p>CVR Energy is trading at US$34.2, below its estimated future cash flow value of US$47.72, highlighting potential undervaluation based on cash flows. Despite a recent Q1 2026 net loss of US$192 million and earnings challenges, the company expects to become profitable within three years with high forecasted return on equity. However, revenue growth remains sluggish at 0.6% annually, trailing the broader U.S market's expectations of 11.2%.</p>
<div class="lb-trans"><p>CVR Energy 的交易價格為 34.2 美元，低於其估計的未來現金流價值 47.72 美元，突顯出基於現金流的潛在低估。儘管最近 2026 年第一季度淨虧損為 1.92 億美元，且面臨盈利挑戰，但該公司預計將在三年內實現盈利，並且預計股本回報率將很高。然而，收入增長仍然緩慢，年增長率為 0.6%，落後於美國市場 11.2% 的預期。</p>
</div><ul>
<li>According our earnings growth report, there's an indication that CVR Energy might be ready to expand.</li>
<li>Navigate through the intricacies of CVR Energy with our comprehensive financial health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>根據我們的收益增長報告，CVR Energy 可能準備擴張的跡象。</li>
<li>通過我們的全面財務健康報告，深入瞭解 CVR Energy 的複雜情況。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85096f12-bc2f-4422-bac7-9d19553b4370/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/85096f12-bc2f-4422-bac7-9d19553b4370/chart/dcf?theme=light"/></p>
<p>CVI Discounted Cash Flow as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 CVI 折現現金流</p>
</div><h2>Unity Software (U)</h2>
<div class="lb-trans"><h2>Unity Software (U)</h2>
</div><p><strong>Overview:</strong> Unity Software Inc. provides a platform for developing, deploying, and enhancing games and interactive experiences across various devices globally, with a market cap of approximately $11.84 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Unity Software Inc.提供一個平台，用於在全球各種設備上開發、部署和增強遊戲及互動體驗，市值約為 118.4 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue from Software Solutions is $1.85 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的軟件解決方案收入為 18.5 億美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 49.9%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 49.9%</p>
</div><p>Unity Software, trading at US$27.72, is significantly undervalued compared to its estimated future cash flow value of US$55.28. Despite recent insider selling and a volatile share price, Unity's strategic moves—such as discontinuing the ironSource Ads Network and divesting Supersonic—aim to enhance revenue growth and margins. The extended partnership with Meta further strengthens its VR platform presence. Unity anticipates profitability within three years, with earnings forecasted to grow substantially at 62.95% annually.</p>
<div class="lb-trans"><p>Unity Software 的交易價格為 27.72 美元，顯著低於其估計的未來現金流價值 55.28 美元。儘管最近內部人士出售股票且股價波動，但 Unity 的戰略舉措——如停止 ironSource 廣告網絡和剝離 Supersonic——旨在提升收入增長和利潤率。與 Meta 的長期合作進一步增強了其虛擬現實平台的存在。Unity 預計將在三年內實現盈利，收益預計將以每年 62.95% 的速度大幅增長。</p>
</div><ul>
<li>The growth report we've compiled suggests that Unity Software's future prospects could be on the up.</li>
<li>Unlock comprehensive insights into our analysis of Unity Software stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們編制的增長報告表明，Unity Software 的未來前景可能向好。</li>
<li>在這份財務健康報告中解鎖我們對 Unity Software 股票分析的全面見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/81b649ee-0ebc-4d90-9c59-c6ef29110c9d/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/81b649ee-0ebc-4d90-9c59-c6ef29110c9d/chart/dcf?theme=light"/></p>
<p>U Discounted Cash Flow as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 U 折現現金流</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Reveal the 151 hidden gems among our Undervalued US Stocks Based On Cash Flows screener with a single click here.</li>
<li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li>
<li>Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏揭示我們基於現金流的 151 只低估美國股票中的隱藏寶藏。</li>
<li>是這些公司的股東之一？確保您不會錯過重要的股票動態，通過在 Simply Wall St 中添加您的投資組合來及時獲取提醒。</li>
<li>通過使用 Simply Wall St 加入聰明投資者的社區。它是免費的，並提供全球市場的專家級分析。</li>
</ul>
</div><h2>Want To Explore Some Alternatives?</h2>
<div class="lb-trans"><h2>想探索一些替代方案嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠的收入來源來分散您的投資組合，以應對潛在的市場波動。</li>
<li>投資於顯示強勁增長潛力的公司，獲得分析師和管理層的樂觀展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是複雜的，但我們在這裏為您簡化它。</h3>
</div><p>Discover if Travere Therapeutics might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通過我們的詳細分析，發現 Travere Therapeutics 是否可能被低估或高估，分析內容包括 <strong>公允價值估算、潛在風險、股息、內部交易和財務狀況。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>獲取免費分析</p>
</div>

3 只股票估計交易價格低於內在價值最多達 49.9%